Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China

Yan Su1*, Hong Qin2*, Chenghao Chen3*, Shengcai Wang4*, Shihuan Zhang1*, Dawei Zhang1, Mei Jin1, Yun Peng1, Leijian He2, Xiaoman Wang2, Suyun Qian3*, Maoquan Qin3*, Ming Ge3, Fuquan Zhang10, Qi Zeng1, Huanmin Wang2, Xiaoli Ma1, Xin Ni1

1Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Key Laboratory of Major Diseases in Children, Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
2Department of Surgical Oncology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
3Department of Thoracic Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
4Department of Otorhinolaryngology Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
5Imaging Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
6Department of Pathology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
7Department of Ultrasound, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
8Pediatric Intensive Care Unit, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
9Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
10Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Correspondence
Xin Ni, Department of Otorhinolaryngology Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Email: nixin@bch.com.cn
Xiaoli Ma, Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Email: mxl1123@vip.sina.com
Huanmin Wang, Department of Surgical Oncology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China.
Email: wanghuanmin@bch.com.cn
Qi Zeng, Department of Thoracic Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China.
Email: zengqi-1@163.com

*These authors contributed equally to this study

Funding source
Capital’s Funds for Health Improvement and Research (No. CFH2018-2-2095)

Received: 29 May, 2020
Accepted: 25 August, 2020

DOI: 10.1002/ped4.12214

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

©2020 Chinese Medical Association. Pediatric Investigation published by John Wiley & Sons Australia, Ltd on behalf of Futaung Research Center of Pediatric Development.
INTRODUCTION

Neuroblastoma is an embryonal tumor that originates from undifferentiated neural crest cells and is the most common extracranial solid tumor in childhood; it constitutes 8%–10% of all childhood malignancies.1,2 Neuroblastoma displays heterogeneity in terms of histology and genetics; thus, recommended treatments and expected outcomes are affected by age, histological variation, and genetic background. Multidisciplinary teams involved in treatment of patients with neuroblastoma include oncology, surgery, radiotherapy, transplantation, imaging, pathology, and psychology.3 Multidisciplinary management has been successfully performed for many types of cancer, with the expectation of improving patient survival.4,5 In 2007, we began to establish a multidisciplinary care approach for the diagnosis and treatment of solid tumors in the Hematology-Oncology Center of Beijing Children’s Hospital. Importantly, we applied this comprehensive multidisciplinary care approach for management of neuroblastoma. In this study, we analyzed the clinical characteristics of children with neuroblastoma who underwent multidisciplinary care from 2007 to 2019 and evaluated their prognoses following receipt of multidisciplinary treatment.

METHODS

Ethical approval

The study was approved by the Ethics Committee of Beijing Children’s Hospital and was conducted in accordance with the Helsinki Declaration. Written informed consent to participate in the study and for publication was obtained from all the patients’ parents before their enrollment in this study.

Patients

From February 2007 to December 2019, 1148 pediatric patients with neuroblastoma were newly diagnosed at the Hematology-Oncology Center of Beijing Children’s Hospital. Fifty-two patients who were discharged from our hospital without any treatment were excluded from this study. Fifty-five high-risk patients who did not complete 13-cis-retinoic acid maintenance treatment were also excluded. Finally, 1041 pediatric patients with neuroblastoma were enrolled in this retrospective study (Figure 1).

Diagnosis and staging

Diagnostic criteria were as follows: (1) Unequivocal pathologic diagnosis was made from tumor tissue by light microscopy (with or without immunohistochemistry,
electron microscopy, and increased urine (or serum) catecholamines or metabolites; or (2) Bone marrow aspirate or trephine biopsy showed unequivocal tumor cells and increased urine (or serum) catecholamines or metabolites.

Clinical stage and risk group: Positron emission tomography-computed tomography, metaiodobenzylguanidine (MIBG) scan, bone scan, bone marrow aspirate and trephine biopsy, enhancement computed tomography, ultrasonographic examination of primary and metastatic tumors, and cranial magnetic resonance imaging were performed to confirm the Image-Defined Risk Factors and determine the clinical stage, in accordance with the International Neuroblastoma Risk Group Staging System. In this study, risk group classification criteria were based on the Children’s Oncology Group before 2011 and on International Neuroblastoma Risk Group after 2011.7,8

Treatment strategies

A multidisciplinary treatment model was implemented with the participation of surgery, radiotherapy, and transplantation teams, under the management of the oncology team.

Chemotherapy: Alternating chemotherapy regimens of CADO and CBVP were applied to patients in low- and intermediate-risk groups. The CADO protocol was applied as follows: cyclophosphamide, 750 mg·m⁻²·d⁻¹, days 1 and 2; adriamycin, 25 mg·m⁻²·d⁻¹, days 1 and 2; vincristine, 1.5 mg·m⁻²·d⁻¹, day 1. The CBVP protocol was applied as follows: carboplatin, 200 mg·m⁻²·d⁻¹, days 1 to 3; etoposide, 150 mg·m⁻²·d⁻¹, days 1 to 3. The dose of cyclophosphamide in the CADO regimen for low- and intermediate-risk groups was 30 mg·kg⁻¹·d⁻¹ in infants younger than 12 months of age. Alternating chemotherapy regimens of CAV and CVP were applied to patients in the high-risk group. CAV was applied as follows: vincristine, 1 mg·m⁻²·d⁻¹, days 1 to 3; adriamycin, 25 mg·m⁻²·d⁻¹, days 1 to 3; cyclophosphamide, 70 mg·m⁻²·d⁻¹, days 1 and 2. The CVP protocol was applied as follows: cisplatin, 50 mg·m⁻²·d⁻¹, days 1 to 4; etoposide, 200 mg·m⁻²·d⁻¹, days 1 to 3. For patients with body weight below 12 kg, the dose of cyclophosphamide in the CAV regimen was reduced by 25%–33%.

Surgery: High-risk neuroblastoma patients without surgical resection at the time of diagnosis were able to undergo surgery after three to four courses of chemotherapy when tumor markers had decreased, bone marrow metastases had become clear, and other metastatic sites were limited.

Patients with low- or intermediate-risk neuroblastoma underwent resection of the primary tumor at the time of diagnosis, or after three to four courses of chemotherapy.

FIGURE 1 Flow diagram of patient enrollment and treatment in this study. HSCT, Hematopoietic stem cell transplantation; CAR-T, chimeric antigen receptor modified T-cells; MIBG, metaiodobenzylguanidine.
According to the tumor site, the departments in our hospital that were involved in the surgery of neuroblastoma included neurosurgery, otorhinolaryngology head and neck surgery, thoracic surgery, and surgical oncology. The otorhinolaryngology head and neck surgery department was responsible for the resection of neck tumors; the surgical oncology department was responsible for the resection of abdominal and pelvic tumors; and the thoracic surgery department was responsible for the resection of thoracic neuroblastoma. Thoracic surgical approaches in this study mainly included thoracoscopy and open thoracotomy. Laminectomy was performed by the neurosurgery department as an initial procedure for patients with serious spinal cord compression caused by tumor invasion.

Radiation therapy: In the intermediate-risk group, patients older than 18 months of age with unfavorable histology were administered radiotherapy on the primary tumor bed at the end of chemotherapy. Radiotherapy was performed on both the primary tumor bed and the sites of persistent metastases in patients with high-risk neuroblastoma at the end of intensive chemotherapy. The radiation dose to primary tumors was 20–25 Gy, while the dose to metastatic tumors was a maximum of 20 Gy.

Hematopoietic stem cell transplantation (HSCT): High-risk patients could be administered myeloablative chemotherapy, followed by autologous hematopoietic stem cell rescue as consolidation treatment. The myeloablative regimen contained carboplatin, 300 mg m⁻²·d⁻¹, days 6 to 3 before transplantation; etoposide, 160 mg m⁻²·d⁻¹, days 6 to 3 before transplantation; melphalan, 140 mg m⁻²·d⁻¹, day 5 before transplantation; melphalan, 70 mg m⁻²·d⁻¹, day 4 before transplantation.

¹³¹I-MIBG and chimeric antigen receptor modified T-cells (CAR-T) therapy: High-risk patients with relapsed or refractory neuroblastoma with MIBG-avid tumors could be administered ¹³¹I-MIBG therapy. Patients with relapsed or refractory neuroblastoma after intensive chemotherapy, surgery, and radiotherapy, with or without HSCT, could be administered CAR-T therapy.

Evaluation

All patients were evaluated by assessment of tumor markers (serum lactate dehydrogenase (LDH), serum neuron specific enolase (NSE), urinary vanillylmandelic acid, urinary homovanillic acid and tumor size, according to risk group and treatment stage. Patients with bone marrow metastasis at the time of diagnosis underwent bone marrow aspirate. Patients with MIBG-avid tumors underwent MIBG scans at the end of intensive therapy. MIBG scans were performed at 6-month intervals in high-risk patients receiving maintenance treatment. The evaluation criteria were established with reference to the Response Evaluation Criteria In Solid Tumors (RECIST) and International Neuroblastoma Response Criteria (INRC).⁹,¹⁰

Follow-up

After discontinuation of drug treatment, patients were followed up at 3-month intervals in years 1 and 2, at 6-month intervals in years 3–5, and at 12-month intervals thereafter. The patients were evaluated with respect to tumor markers, imaging of primary and metastatic tumors and bone marrow aspirate (solely for patients with prior bone marrow metastasis). The evaluation also included monitoring of therapeutic toxicity, such as hepatic and renal function, cardiac function, and audition. Event-free survival (EFS) was defined as the interval from the day of diagnosis to an event or date of last follow-up (if no event occurred). An event was defined as the first occurrence of relapse or progression of neuroblastoma, secondary malignancy, or death for any reason. Overall survival (OS) was defined as the interval from the day of diagnosis to death for any reason or date of last follow-up (if no death occurred). Early death was defined as death within 1 month after diagnosis of neuroblastoma. The final follow-up cutoff date was April 30th, 2020.

Statistical methods

Statistical analyses were performed using IBM SPSS Statistics for Windows, version 19.0 (IBM Corp., Armonk, NY, USA). Data with non-normal distributions are expressed as medians (ranges); the Wilcoxon signed-rank test was used for comparisons of these data between groups. Qualitative data are presented as counts (percentages); the chi-squared (χ²) test was used for comparisons of these data between groups. Log-rank tests were used to compare differences in survival estimates between variables. Cox proportional hazards regression analysis was used to investigate risk factors that might influence OS. Survival plots were constructed using the Kaplan–Meier method. P < 0.05 was considered as statistical significance.

RESULTS

Clinical data

The 1041 patients with neuroblastoma in this study comprised 541 boys and 500 girls with a median age of 34 months (range, 0–191 months). Children younger than 5 years of age comprised 80.8% of the patients, while children older than 10 years of age comprised only 1.6% of the patients. The median largest primary tumor diameter was 7.9 cm (range, 0.9–29.0 cm), the median level of serum NSE was 89.5 ng/mL (range, 5.1–2370.0 ng/mL), the median level of serum LDH was 388.5 U/L (range, 117.0–17324.0 U/L), the median level of serum neuron specific enolase (NSE) was 89.5 ng/mL (range, 5.1–2370.0 ng/mL).
intermediate-risk groups. Moreover, 109 (16.4%) patients with primary tumor sites in the retroperitoneal or adrenal region exhibited \textit{MYCN} amplification. The primary tumor sites of 307 patients were located in the thorax, including 82 (26.7%) in the high-risk group and 225 (73.3%) in the low- and intermediate-risk groups; furthermore, five patients with primary tumor sites in the thorax exhibited \textit{MYCN} amplification. Among patients with primary tumors outside the retroperitoneal and thoracic regions, 22 were in the high-risk group and 47 were in the low- and intermediate-risk groups; no patients with primary tumors outside the retroperitoneal and thoracic regions exhibited \textit{MYCN} amplification. The clinical characteristics of the 1041 patients are shown in Table 1.

### **Table 1** Clinical characteristics of pediatric patients with neuroblastoma \((n = 1041)\)

| Characteristics                      | Number of patients, \(n\) (%) | Characteristics                      | Number of patients, \(n\) (%) |
|--------------------------------------|-------------------------------|--------------------------------------|-------------------------------|
| Gender                               |                               | \textit{MYCN} status                |                               |
| Male                                 | 541 (52.0)                    | Amplified                            | 114 (11.0)                    |
| Female                               | 500 (48.0)                    | Non-amplified                        | 887 (85.2)                    |
| Unknown                              |                               | Unknown                              | 40 (3.8)                      |
| Age at diagnosis (months)            |                               | Years of treatment                   |                               |
| <18                                  | 277 (26.6)                    | 2007–2010                            | 67 (6.4)                      |
| 18–60                                | 564 (54.2)                    | 2011–2014                            | 212 (20.4)                    |
| 60–120                               | 183 (17.6)                    | 2015–2019                            | 762 (73.2)                    |
| ≥120                                 | 17 (1.6)                      |                                       |                               |
| Primary tumor site                   |                               | Surgery                              |                               |
| Retroperitoneal/adrenal              | 665 (63.9)                    | In our hospital                       | 824 (79.1)                    |
| thoracic                             | 307 (29.5)                    | Surgical Oncology                    | 530 (50.9)                    |
| Neck                                 | 27 (2.6)                      | Thoracic Surgery                     | 237 (22.7)                    |
| Pelvic                               | 20 (1.9)                      | Head and Neck Surgery                | 22 (2.1)                      |
| Two body compartments                | 12 (1.1)                      | Neurosurgery                         | 3 (0.3)                       |
| \(^{†}\)Others                      | 10 (1.0)                      | Two surgery departments              | 32 (3.1)                      |
| NSE (ng/mL)                          |                               | In other hospital                     | 132 (12.7)                    |
| <100                                 | 546 (52.4)                    | No surgery                           | 85 (8.2)                      |
| ≥100                                 | 495 (47.6)                    |                                       |                               |
| LDH (U/L)                            |                               | Chemotherapy                         |                               |
| <500                                 | 644 (61.9)                    | Yes                                  | 986 (94.7)                    |
| 500–1500                             | 272 (26.1)                    | No                                   | 55 (5.3)                      |
| ≥1500                                | 125 (12.0)                    | Radiation therapy                    |                               |
| Bone marrow metastasis               |                               | Yes                                  | 525 (50.4)                    |
| Yes                                  | 438 (42.1)                    | No                                   | 516 (49.6)                    |
| No                                   | 603 (57.9)                    | HSCT                                 |                               |
| Bone metastasis                      |                               | Yes                                  | 176 (16.9)                    |
| Yes                                  | 417 (40.1)                    | No                                   | 865 (83.1)                    |
| No                                   | 624 (59.9)                    | MIBG therapy                         |                               |
| Distant lymph node metastasis        |                               | Yes                                  | 66 (6.3)                      |
| Yes                                  | 375 (36.1)                    | No                                   | 975 (93.7)                    |
| No                                   | 665 (63.9)                    | CAR-T therapy                        |                               |
|                                       |                               | Yes                                  | 19 (1.8)                      |
|                                       |                               | No                                   | 1022 (98.2)                   |

\(^{†}\)Others: skull base, intraspinal canal, no primary foci. NSE, neuron specific enolase; LDH, lactate dehydrogenase; HSCT, hematopoietic stem cell transplantation; MIBG, metaiodobenzylguanidine; CAR-T, chimeric antigen receptors modified T-cells.
22.0 months (range, 0.2–154.0 months) until April 30, 2020. The 3-year OS rate was 72.1%, while the 5-year OS rate was 66.4%. The 3-year EFS rate of 1041 patients was 63.1%, while the 5-year EFS rate was 57.3% (Figure 2). The 5-year EFS rates were 91.3%, 85.1%, and 37.7% when patients were stratified into low-risk, intermediate-risk, and high-risk groups, respectively. The 5-year OS rates were 97.5%, 96.7%, and 48.9% when patients were stratified into low-risk, intermediate-risk, and high-risk groups, respectively (EFS: $\chi^2 = 195.772, P < 0.001$; OS: $\chi^2 = 158.055, P < 0.001$) (Figure 3A, B). The 5-year EFS rates were 47.4%, 47.4%, and 62.9% in patients who were diagnosed and treated in the following subdivisions of the study period: 2007–2010, 2011–2014, and 2015–2019, respectively. The respective 5-year OS rates were 55.4%, 54.8%, and 71.1% in patients who were diagnosed and treated in those three subdivisions of the study period (Figure 4A, B). The EFS and OS rates of patients who were diagnosed and treated in the 2015–2019 subdivision were significantly higher than patients who were diagnosed and treated in the prior subdivisions (EFS: $\chi^2 = 20.277, P < 0.001$; OS: $\chi^2 = 31.924, P < 0.001$).

### Treatment

In total, 956 patients underwent surgical resection of primary tumors or metastases; of these, 824 underwent surgical resections in our hospital, while the remaining 132 patients underwent surgeries in other hospitals. In three subdivisions of the study period (2007–2010, 2011–2014, and 2015–2019), the proportions of patients with neuroblastoma who underwent surgery in our hospital were 70.0%, 76.8%, and 80.5%, respectively. Of 307 patients with primary thoracic tumor, 237 (77.2%) underwent surgical resection in the thoracic surgery department in our hospital. Thoracoscopic resections were performed in 166 patients, open thoracotomy approaches in 68 patients, and resections from the neck in three patients. Of 691 patients with primary abdominal and pelvic tumors, 530 (76.7%) underwent surgical resection in the surgical oncology department in our hospital. Of 27 patients with primary tumors located in the neck, 22 (81.5%) underwent surgical resection in the otolaryngology head and neck surgery department in our hospital. Thirty-two patients underwent surgery involving two surgical departments; of these 32 patients, 28 (87.5%) had severe spinal cord compression caused by tumor invasion into the spinal canal. For these 28 patients, spinal canal decompression was performed in the neurosurgery department, followed by chemotherapy and resection of primary tumors in the surgical oncology or thoracic surgery departments.

In total, 986 patients received chemotherapy; 55 patients with very low- or low-risk neuroblastoma only underwent surgery and subsequent observation. Notably, 437 patients with low- or intermediate-risk neuroblastoma received chemotherapy, with a median of five courses of chemotherapy (range, 2–9 courses) (Figure 1).

### Prognosis

The median follow-up period for all 1041 patients was...
Univariate survival analysis showed that retroperitoneal/adrenal tumors, NSE ≥ 100 ng/mL, LDH ≥ 1500 U/L, largest primary tumor diameter ≥ 7.9 cm, bone metastasis, bone marrow metastasis, and distant lymph node metastasis were associated with poor prognosis in patients with low- and intermediate-risk neuroblastomas (all P < 0.05) (Table 2). Bone marrow metastasis (HR: 4.730; 95% CI: 1.290–17.335; P < 0.05) and LDH ≥ 1500 U/L (HR: 3.801; 95% CI: 1.470–9.828; P < 0.05) were poor prognostic factors for survival of patients with low- and intermediate-risk neuroblastomas, according to Cox regression models.

Univariate survival analysis showed that NSE ≥ 100 ng/mL, LDH ≥ 1500 U/L, bone metastasis, bone marrow metastasis, and MYCN amplification were associated with poor prognosis in patients with high-risk neuroblastoma (all P < 0.05) (Table 3). Bone marrow metastasis, LDH ≥ 1500 U/L, and MYCN amplification were poor prognostic factors for survival of patients with high-risk neuroblastoma, according to Cox regression models (HR: 1.812, 1.712, and 1.754, respectively; 95% CI: 1.272–2.582, 1.424–2.059, and 1.426–2.157, respectively; all P < 0.05).

In total, 278 patients (86.8%) experienced tumor relapse or progression at a median of 14 months (range, 1–72 months). Relapse or progression occurred in 31 patients (11.2%) with low- or intermediate-risk groups; of these, 21 patients (67.7%) exhibited relapse or progression at primary tumor sites. The 5-year OS rates were 22.7% in patients with relapse or progression who underwent MIBG treatment and 17.1% in patients with relapse or progression who did not undergo MIBG treatment (χ² = 5.541, P = 0.019). The 5-year OS rates were 32.0% in patients with relapse or progression who underwent CAR-T treatment and 16.8% in patients relapse or progression who did not undergo CAR-T treatment (χ² = 3.610, P = 0.057). Three patients in high-risk group developed secondary malignant neoplasms, comprising acute leukemia, thyroid cancer, and Ewing’s sarcoma of the leg at 54 months, 20 months, and 69 months after the diagnosis of neuroblastoma, respectively.

| Characteristics                      | Number of patients, n (%) | 5-year OS (%) | P      |
|--------------------------------------|---------------------------|---------------|--------|
| Gender                               |                           |               | 0.231  |
| Male                                 | 227 (46.1)                | 97.9          |        |
| Female                               | 265 (53.9)                | 96.2          |        |
| Age at diagnosis (months)            |                           |               | 0.047  |
| <18                                  | 246 (50.0)                | 95.9          |        |
| ≥18                                  | 246 (50.0)                | 98.2          |        |
| Risk group                           |                           |               | 0.865  |
| Very low/low                         | 243 (49.4)                | 97.5          |        |
| Intermediate                         | 249 (50.6)                | 96.7          |        |
| Primary tumor site                   |                           |               | 0.047  |
| Retroperitoneal/adrenal              | 220 (44.7)                | 94.9          |        |
| Thoracic                             | 225 (45.7)                | 98.4          |        |
| Others                               | 47 (9.6)                  | 100           |        |
| NSE (ng/mL)                          |                           |               | <0.001 |
| <100                                 | 400 (81.3)                | 98.6          |        |
| ≥100                                 | 92 (18.7)                 | 89.8          |        |
| LDH (U/L)                            |                           |               | <0.001 |
| <500                                 | 446 (90.7)                | 98.0          |        |
| 500–1500                             | 43 (8.7)                  | 92.3          |        |
| ≥1500                                | 3 (0.6)                   | 0             |        |
| The longest diameter of primary tumor (cm) |                     |               | 0.032  |
| <7.9                                 | 356 (72.4)                | 98.2          |        |
| ≥7.9                                 | 136 (27.6)                | 93.9          |        |
| Bone marrow metastasis               |                           |               | <0.001 |
| Yes                                  | 29 (5.9)                  | 82.2          |        |
| No                                   | 463 (94.1)                | 98.0          |        |
| Bone metastasis                      |                           |               | 0.028  |
| Yes                                  | 35 (7.1)                  | 89.9          |        |
| No                                   | 457 (92.9)                | 97.6          |        |
| Distant lymph node metastasis        |                           |               | 0.005  |
| Yes                                  | 43 (8.7)                  | 89.5          |        |
| No                                   | 449 (91.3)                | 97.7          |        |

<sup>1</sup> Others: primary tumor sites except retroperitoneal/adrenal and thoracic sites. OS, overall survival; NSE, neuron specific enolase; LDH, lactate dehydrogenase.
infection during transplantation or chemotherapy and two died of therapy-related complications, eight died of severe therapy-related complications. Of the 10 patients who metastases or critical disease, and 10 (4.3%) died of neuroblastoma relapse or progression, 12 (5.2%) overall, 233 patients (22.4%) died, of whom 194 (83.3%) died of neuroblastoma relapse or progression, 12 (5.2%) died of tumor rupture, 17 (7.3%) died of extensive metastases or critical disease, and 10 (4.3%) died of therapy-related complications. Of the 10 patients who died of therapy-related complications, eight died of severe infection during transplantation or chemotherapy and two died of operation-related complications. The median age at diagnosis of the 12 patients who died of tumor rupture was 31 months (range, 19–103 months). Among these 12 patients, 11 exhibited high-risk neuroblastoma and the primary tumor sites were located in the retroperitoneal or adrenal region. The median interval until tumor rupture was 5 days after diagnosis of neuroblastoma (range, 0–20 days). Rupture occurred after chemotherapy in two patients and before chemotherapy in 10 patients. All patients with tumor rupture were treated with chemotherapy and coagulation factor support therapy, without surgical intervention. The age at diagnosis, the largest primary tumor diameter, and LDH level were compared among patients with different causes of death. The median age was lowest in patients with therapy-related death (15.5 months; range, 8.0–55.5 months; \( P < 0.001 \)). The median primary tumor diameter was largest in patients who died of tumor rupture (14.5 cm; range, 10.8–26.0 cm; \( P = 0.006 \)). The median level of LDH was highest in patients who died of tumor rupture (2785 U/L; range, 1087–8356 U/L; \( P < 0.001 \)). Patients who died of extensive metastases or critical disease also had higher LDH and larger primary tumor diameter, compared with patients who died of relapse or progression and therapy-related complications (Figure 5A–C). Twenty-seven patients died within one month of diagnosis; of these, 12 died of tumor rupture and 15 died of extensive metastases or critical conditions.

**DISCUSSION**

The Hematology-Oncology Center of Beijing Children’s Hospital began to systematically diagnose and treat neuroblastoma in 2007. With improved management experience and extensive multidisciplinary collaboration, the OS of patients with neuroblastoma has been improved each year. Following comprehensive cooperation with surgery, transplantation, and radiotherapy departments beginning in 2015, the treatment flow of patients has become increasingly efficient. The 5-year EFS rate and 5-year OS rate were significantly improved after 2015, compared with previous periods (\( P < 0.05 \)). Notably, the follow-up duration for some patients treated after 2015 is relatively short; additional follow-up time is needed to confirm the long-term effects in these patients.

Overall, 233 patients (22.4%) died, of whom 194 (83.3%) died of neuroblastoma relapse or progression, 12 (5.2%) died of tumor rupture, 17 (7.3%) died of extensive metastases or critical disease, and 10 (4.3%) died of therapy-related complications. Of the 10 patients who died of therapy-related complications, eight died of severe infection during transplantation or chemotherapy and two died of operation-related complications. The median age

### Table 3: Univariate survival analysis of 549 patients with high-risk neuroblastoma

| Characteristics          | Number of patients, n (%) | 5-year OS (%) | \( P \) |
|--------------------------|---------------------------|---------------|-------|
| Gender                   |                           |               |       |
| Male                     | 314 (57.2)                | 46.8          | 0.269 |
| Female                   | 235 (42.8)                | 51.5          |       |
| Age at diagnosis (months)|                           |               |       |
| <18                      | 31 (5.6)                  | 51.3          | 0.591 |
| ≥18                      | 518 (94.4)                | 48.6          |       |
| Primary tumor site       |                           |               |       |
| Retroperitoneal/adrenal  | 44 (81.1)                 | 45.5          | 0.059 |
| Thoracic                 | 82 (14.9)                 | 62.1          |       |
| Others                   | 22 (4.0)                  | 67.7          |       |
| NSE (ng/mL)              |                           |               |       |
| <100                     | 146 (26.6)                | 59.4          | 0.010 |
| ≥100                     | 403 (73.4)                | 44.6          |       |
| LDH (U/L)                |                           |               |       |
| <500                     | 198 (36.1)                | 61.4          | <0.001|
| 500–1500                 | 229 (41.7)                | 50.3          |       |
| ≥1500                    | 122 (22.2)                | 24.8          |       |
| The longest diameter of primary tumor (cm) |                   |               |       |
| <7.9                     | 173 (31.5)                | 50.1          | 0.426 |
| ≥7.9                     | 376 (68.5)                | 48.2          |       |
| Bone marrow metastasis   |                           |               |       |
| Yes                      | 409 (74.5)                | 41.4          | <0.001|
| No                       | 140 (25.5)                | 68.7          |       |
| Bone metastasis          |                           |               |       |
| Yes                      | 382 (69.6)                | 43.3          | 0.009 |
| No                       | 167 (30.4)                | 61.8          |       |
| Distant lymph node metastasis |                       |               |       |
| Yes                      | 332 (60.5)                | 49.4          | 0.385 |
| No                       | 217 (39.5)                | 48.2          |       |
| MYCN status              |                           |               | <0.001|
| Amplified                | 114 (20.8)                | 30.5          |       |
| Non-amplified            | 397 (72.3)                | 55.5          |       |
| Unknown                  | 38 (6.9)                  | 29.6          |       |
| HSCT                     |                           |               | 0.543 |
| Yes                      | 176 (32.1)                | 45.3          |       |
| No                       | 373 (67.9)                | 52.4          |       |
| MIBG therapy             |                           |               | 0.970 |
| Yes                      | 66 (12.0)                 | 38.8          |       |
| No                       | 483 (88.0)                | 50.9          |       |
| CAR-T therapy            |                           |               |       |
| Yes                      | 19 (3.5)                  | 46.1          | 0.734 |
| No                       | 530 (96.5)                | 49.3          |       |

†Others indicate primary tumor sites except retroperitoneal/adrenal and thoracic sites. OS, overall survival; NSE, neuron specific enolase; LDH, lactate dehydrogenase; HSCT, hematopoietic stem cell transplantation; MIBG, metaiodobenzylguanidine; CAR-T, chimeric antigen receptors modified T-cells.
that thoracoscopic was a safe, effective approach for the resection and biopsy of solid lung tumors in a study of 134 children with solid thoracic tumors. Malek et al. compared the outcomes of thoracoscopic resection and open thoracotomy in 36 patients with thoracic neuroblastoma. They showed that thoracoscopic resection could facilitate shorter length of stay, milder pain, and less blood loss. There were no significant differences in complications, recurrence, survival, or disease-free survival between the two groups. Notably, 7%–15% of patients with neuroblastoma will experience spinal cord compression, due to giant tumors that extend into the spinal canal. These patients present with neurological motor deficits or sphincter dysfunction. Long-term or severe compression may lead to permanent neurological dysfunction. Patients with severe spinal cord compression have been shown to benefit from neurosurgical intervention. In the present study, 28 patients with intraspinal extension of abdominal or thoracic neuroblastoma underwent spinal canal decompression surgery by the neurosurgery department in our hospital. Following chemotherapy and subsequent primary tumor resection, 90% of the patients exhibited complete recovery of neurological motor deficit and sphincter dysfunction.

High-risk neuroblastoma is routinely treated with intensive chemotherapy, surgery, radiotherapy, and 13-cis-retinoic acid maintenance in China. Some patients receive myeloablative chemotherapy, followed by autologous hematopoietic stem cell rescue as consolidation therapy. However, survival remains poor for children with neuroblastoma relapse or progression. Survival of patients with relapsed high-risk neuroblastoma is currently <10%. At the time of first relapse, 60% of patients have been reported to relapse within 18 months, while 80% have been reported to relapse within 24 months of diagnosis. In the present study, the median interval until tumor relapse or progression was 14 months; 88.8% of patients exhibited high-risk neuroblastoma. This time was the later period of maintenance treatment or just termination of therapy in high-risk neuroblastoma. In the present study, patients with tumor relapse or progression received further intensive chemotherapy, MIHG treatment, or CAR-T treatment. CAR-T therapy for patients with relapsed or refractory neuroblastoma has been considered safe and feasible since the early 2000s. There are currently many open clinical trials of CAR-T therapy for patients with relapse or progression neuroblastoma. Our data showed that CAR-T therapy was well tolerated; it provided a short-term therapeutic effect for patients with refractory and recurrent neuroblastoma. However, it did not improve the long-term survival rate. Tumor relapse and progression are the major challenges in treatment of patients with high-risk neuroblastoma. This is a therapeutic limitation for patients with high-risk neuroblastoma in China. In recent years, immunotherapy involving the anti-GD2 antibody has further improved the survival of patients with high-risk neuroblastoma. A phase 3 randomized clinical trial of the Children’s Oncology Group showed that immunotherapy with ch14.18 was associated with a significantly improved outcome, compared with standard therapy, in patients with high-risk neuroblastoma. Immunotherapy was superior to standard therapy with respect to rates of 2-year EFS (66% vs. 46%, P = 0.01) and 2-year OS (86% vs. 75%, P = 0.02). Another phase 3 randomized clinical trial of SIOPEN showed that the 5-year EFS rate was 53% and 5-year OS rate was 63% in patients with high-risk neuroblastoma who received anti-GD2 antibody ch14.18/CHO treatment.

The prognoses of patients with low- and intermediate-risk neuroblastoma are much better than those of patients with high-risk neuroblastoma. In the present study, 31 patients with low- or intermediate-risk neuroblastoma exhibited tumor relapse or progression; of these 31 patients, 67.7% exhibited relapse or progression at the primary tumor site. The causes of relapse or progression were related to the biological characteristics of the tumor (e.g., unfavorable histology), extensive metastases in some infants, and partial resection of the tumor in patients with large residual lesions. SIOP reports showed that gross resection or subtotal resection was an important factor for cure in patients with localized neuroblastoma who did not exhibit MYCN amplification. However, patients older than 18 months of age with unfavorable histopathology and elevated LDH exhibited a high number of relapses.

FIGURE 5 Correlation analysis of (A) Age at diagnosis; (B) Largest primary tumor diameter; (C) LDH level in patients with different causes of death. LDH, lactate dehydrogenase.
Therefore, the surgeon’s technique and the degree of surgical resection of the primary tumor are important factors in the prognosis of low- and intermediate-risk neuroblastoma.

Treatment advances have led to significantly improved outcomes for children with neuroblastoma; consequently, the number of survivors is increasing. During the past four decades, high-risk patients have been treated with increasingly intensive and multi-modal approaches. Neuroblastoma survivors are at enhanced risk of developing secondary malignant neoplasms, compared with the general population. In this study, three patients with high-risk neuroblastoma developed secondary malignant neoplasms, including acute leukemia, thyroid cancer, and Ewing’s sarcoma; notably, the sites of secondary solid tumors were not the radiotherapy sites of neuroblastoma. Applebaum et al. analyzed 2801 neuroblastoma patients and found that 34 (1.2%) developed secondary malignant neoplasms, including renal cell carcinoma, thyroid cancer, acute myeloid leukemia, sarcoma, and lymphoma. Furthermore, 14.7% of secondary malignant neoplasms occurred at the site of radiotherapy for the primary neuroblastoma tumor. The incidence of secondary malignancy was relatively low in the present study, presumably because of the shorter treatment time for patients with neuroblastoma in our center and the shorter follow-up interval for our patients.

The risks of early death due to acute leukemia, hepatoblastoma, or brain tumor are significantly greater than the risk of death due to neuroblastoma in children. Age younger than 1 year was considered to be a risk factor for early death in patients with solid tumors. The early death in this study mainly occurred in patients with tumor rupture, extensive metastases, or critical diseases. Moreover, the primary tumor diameter and LDH level were significantly greater in patients with tumor rupture, extensive metastases, or critical diseases. Qin et al. analyzed 47 cases with tumor rupture, which revealed that a primary tumor diameter >13.2 cm was an independent risk factor for tumor rupture in children with neuroblastoma. The LDH level was significantly higher in patients with tumor rupture than in patients without tumor rupture. Clinicians should carefully monitor patients with high LDH and large tumors to reduce the risk of death due to tumor rupture and critical diseases. In the present study, the median age was lowest among patients with therapy-related death (15.5 months), compared with other causes of death. Because infants are less able to tolerate aggressive treatment, clinicians should perform careful management of young patients with neuroblastoma. Tumor relapse and progression remain the primary causes of death in patients with neuroblastoma. With respect to death caused by tumor relapse or progression, more comprehensive multidisciplinary care approaches and more effective therapeutic methods are essential to improve the prognosis of patients with neuroblastoma.

The management of neuroblastoma by a multidisciplinary care approach in Hematology-Oncology Center of Beijing Children’s Hospital has been ongoing for more than 10 years. In this study, the 5-year OS rates of low-, intermediate- and high-risk patients were 97.5%, 96.7%, and 48.9%, respectively. Moreover, the therapy-related mortality rate was 4.3%. Notably, 80% of the surgeries were performed by surgical teams in our hospital. Multidisciplinary cooperation is an important approach for improving the survival of patients with neuroblastoma. More effective therapeutic methods should be designed to improve the prognoses of these patients.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202-2211.
2. Pinto NR, Applebaum MA, Volchenboum SL, Matthey KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008-3017.
3. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Sage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369-386.
4. Slavova-Azmanova NS, Johnson CE, Platell C, Bydder S, Saunders CM. Peer review of cancer multidisciplinary teams: is it acceptable in Australia? Med J Aust. 2015;202:144-147.
5. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: Are they effective in the UK? Lancet Oncol. 2006;7:935-943.
6. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol.1993;11:1466-1477.
7. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol. 2009;27:289-297.
8. PDQ® Pediatric Treatment Editorial Board. PDQ Neuroblastoma Treatment. Bethesda, MD: National Cancer Institute. https://www.cancer.gov/types/neuroblastoma/hp/ neuroblastoma-treatment-pdq. Accessed May 1, 2020.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
10. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning
11. Chang HH, Liu YL, Lu MY, Jou ST, Yang YL, Lin DT, et al. A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients. Oncotarget. 2017;8:4360-4372.

12. Guye E, Lardy H, Piolat C, Bawab F, Becmeur F, Dyk JF, et al. Thoracoscopy and solid tumors in children: A multicenter study. J Laparoendosc Adv Surg Tech A. 2007;17:825-829.

13. Malek MM, Mollen KP, Kane TD, Shah SR, Irwin C. Thoracic neuroblastoma: A retrospective review of our institutional experience with comparison of the thoracoscopic and open approaches to resection. J Pediatr Surg. 2010;45:1622-1626.

14. Kraal K, Blom T, van Noesel M, Kremer L, Caron H, Tytgat G, et al. Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review. Pediatr Blood Cancer. 2017;64 doi:10.1002/pbc.26451.

15. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-1057.

16. Richards RM, Sotillo E, Majzner RG. CAR T cell therapy for neuroblastoma. Front Immunol. 2018;9:2380.

17. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-1334.

18. Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): A multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617-1629.

19. Kohler JA, Rubie H, Castel V, Beiske K, Holmes K, Gambini C, et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study. Eur J Cancer. 2013;49:3671-3679.

20. De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008;99:1027-1033.

21. Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL. Second malignancies in patients with neuroblastoma: The effects of risk-based therapy. Pediatr Blood Cancer. 2015;62:128-133.

22. Green AL, Furutani E, Ribeiro KB, Galindo CR. Death within 1 month of diagnosis in childhood cancer: An analysis of risk factors and scope of the problem. J Clin Oncol. 2017;35:1320-1327.

23. Qin H, Yang S, Cai S, Ren Q, Han W, Yang W, et al. Clinical characteristics and risk factors of 47 cases with ruptured neuroblastoma in children. BMC Cancer. 2020;20:243.

How to cite this article: Su Y, Qin H, Chen C, Wang S, Zhang S, Zhang D, et al. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatr Investig. 2020;4:157-167. https://doi.org/10.1002/ped4.12214